Isomorphic Labs Raises $2.1B in Series B Led by Thrive Capital

According to Bloomberg, Isomorphic Labs, a drug discovery company spun out of Google DeepMind in 2021, raised $2.1 billion in a Series B funding round led by Thrive Capital on May 12. Alphabet, MGX, Temasek, CapitalG, GV, and the UK Sovereign AI Fund also participated in the round.

The company will use the funding to expand its AI drug design engine IsoDDE and hire across AI, engineering, drug design, and clinical teams. Isomorphic Labs has partnerships with pharmaceutical companies including Eli Lilly and Novartis.

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Comment
0/400
No comments